Raymond James Upgrades CubeSmart to Market Perform

Raymond James analyst Jonathan Hughes upgrades CubeSmart (NYSE:CUBE) from Underperform to Market Perform.

byBenzinga Newsdesk

August 10, 2021

1 minute read

Raymond James analyst Jonathan Hughes upgrades CubeSmart (NYSE:CUBE) from Underperform to Market Perform.

CORRECTION: Mizuho Reiterates Buy on WEX, Raises Price Target to $220 – Price Target Updated

By Benzinga Newsdesk

Today, 3:20 AM

CORRECTION: Mizuho analyst Dan Dolev reiterates WEX (NYSE:WEX) with a Buy and raises the price target from $200 to $220, price target updated.

WEX

Perma-Pipe Inlt Hldgs Q2 EPS $0.41 Up From $0.03 YoY, Sales $39.80M Up From $20.36M YoY

By Benzinga Newsdesk

Today, 3:20 AM

Perma-Pipe Inlt Hldgs (NASDAQ:PPIH) reported quarterly earnings of $0.41 per share. This is a 1266.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported $39.80 million

PPIH

Schrödinger Announces FDA Clearance Of Investigational New Drug Application For SGR-1505, A MALT1 Inhibitor

By Bill Haddad

Today, 3:20 AM

Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform

SDGR

Truist Securities Initiates Coverage On Teladoc Health with Hold Rating, Announces Price Target of $35

By Benzinga Newsdesk

Today, 3:20 AM

Truist Securities analyst Jailendra Singh initiates coverage on Teladoc Health (NYSE:TDOC) with a Hold rating and announces Price Target of $35.

TDOC

Raymond James Upgrades CubeSmart to Market Perform

Related Posts

CORRECTION: Mizuho Reiterates Buy on WEX, Raises Price Target to $220 – Price Target Updated

Perma-Pipe Inlt Hldgs Q2 EPS $0.41 Up From $0.03 YoY, Sales $39.80M Up From $20.36M YoY

Schrödinger Announces FDA Clearance Of Investigational New Drug Application For SGR-1505, A MALT1 Inhibitor

Truist Securities Initiates Coverage On Teladoc Health with Hold Rating, Announces Price Target of $35